결핵 치료 준수를 개선하기위한 약사 주도의 디지털 중재 (CARE-TB)
말레이시아 셀랑 고르에서 결핵 환자 (Care-TB 연구)에 대한 치료 준수를 최적화하기위한 포괄적 인 디지털 준수 및 원격 참여 : 효율성 구현 과학 연구
The gold standard for tuberculosis (TB) treatment support requires directly observed therapy (DOT), which means a trained health worker observes the patient swallow each dose of medication every day for 2 months. Despite the practice of DOT in Malaysia, 1 in 20 patients are loss-to-follow-up and non-adherent to treatment. Sub-optimal adherence due to poor treatment acceptability and social desirability promotes TB treatment failure, disease relapse, on-going transmission, drug resistance, and death. Telemedicine offers a flexible and less invasive option to support TB treatment adherence. Despite 97% internet and smartphone penetration rates, the practical implementation of digital adherence strategies to support and monitor TB treatment remains untested in Malaysia. The investigators propose to design, implement, and measure the effectiveness of a comprehensive, pharmacist-led digital solution for TB treatment support called CARE-TB which combines a package of asynchronous video-observed therapy, digital reminders, telecounselling and e-learning. In this multi-method effectiveness-implementation (Type 2) study using the Exploration, Preparation, Implementation and Sustainment (EPIS) framework, the investigators aim 1) To identify patient and provider-level facilitators and barriers to CARE-TB adoption via qualitative evaluation and to design a stakeholder-informed implementation strategy, (2) To assess effectiveness of CARE-TB strategy by evaluating (i) implementation outcomes, (ii) patient health outcomes, and (iii) service outcomes, and (3) To evaluate the cost-effectiveness of CARE-TB compared to standard of care from a societal perspective. This study will leverage digital platforms to expand the reach of TB adherence support, enhance adherence to TB treatment and improve treatment completion rates, while utilising existing personnel and resources in among the busiest TB treatment centres in the country.
연구 개요
연구 유형
등록 (실제)
단계
- 해당 없음
연락처 및 위치
연구 장소
-
-
Selangor
-
Sungai Buloh, Selangor, 말레이시아, 47000
- Sungai Buloh Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Microbiologically confirmed TB
- 18 years old or older
- Able to give consent and physically able to participate in the study
- Own a video-recording device with internet connectivity
- Within the first 3 weeks of intensive phase TB treatment
Exclusion Criteria:
- Complicated TB disease including TB meningitis, TB bone/joint, and disseminated TB with planned treatment duration of 9 to 12 months.
- Confirmed or suspected drug-resistant (DR)-TB
- Documented cognitive, motor, or visual disability that will hinder video device use and lack assistance of a caretaker
- Receiving injectable anti-TB drugs
- Incarceration or other involuntary detention
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 지지 요법
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
활성 비교기: Standard care arm
Directly observed therapy (healthcare or caretaker-based) |
Directly observed therapy at any government healthcare facility (by nurses) or at home (by caretaker)
다른 이름들:
|
|
실험적: CARE-TB arm
CARE-TB package includes pharmacist-led asynchronous video observed therapy, digital medication reminders, telecounselling and e-learning for patients. |
CARE-TB package includes pharmacist-led asynchronous video observed therapy, digital medication reminders, telecounselling and e-learning for patients.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Medication adherence (Binary outcome)
기간: 8 weeks following enrollment
|
Completed ≥ 80% scheduled observations during the 8 weeks following enrolment. |
8 weeks following enrollment
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Adherence rate (Continuous outcome)
기간: 8 weeks following enrolment
|
Proportion of doses observed over 8 weeks (Dose observed divided by total observable doses prescribed) |
8 weeks following enrolment
|
|
Proportion of TB treatment completion, death, loss to follow up, and hospitalization
기간: From enrolment till 6 months or treatment completion/ termination
|
Proportion of patients completing TB treatment, died, are lost to follow-up or hospitalized during TB treatment |
From enrolment till 6 months or treatment completion/ termination
|
|
TB cure rate
기간: At 6 months of treatment
|
Proportion of microbiological TB clearance (e.g. AFB smear/ MTB PCR/ MTB culture) |
At 6 months of treatment
|
|
Adverse event reporting
기간: From enrolment till 6 months of treatment
|
Number of adverse events or adverse drug reactions reported during TB treatment |
From enrolment till 6 months of treatment
|
|
EQ-5D-5L Health-related Quality of Life (HRQoL)
기간: At baseline, 2 months and 6 months of treatment
|
HRQoL will be assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire. Unit of Measure: EQ-5D index score (range: -0.281 to 1.000 based on country-specific value set) Interpretation: Higher scores indicate better health-related quality of life. |
At baseline, 2 months and 6 months of treatment
|
|
SF-12 Health-related Quality of Life (HRQoL)
기간: At baseline and 2 months of treatment
|
The 12-Item Short Form Survey (SF-12) will be used to assess participants' health-related quality of life. Two summary scores will be generated: the Physical Component Summary (PCS) and the Mental Component Summary (MCS). The scoring scale is from 0 to 100, the higher the score the better the health related quality of life. |
At baseline and 2 months of treatment
|
|
Implementation Outcomes: Acceptability, Feasibility, Appropriateness (Quantitative measure)
기간: At 2 months and 6 months of treatment
|
Implementation outcomes will be assessed using the combined Acceptability of Intervention Measure (AIM), Feasibility of Intervention Measure (FIM), and Intervention Appropriateness Measure (IAM) questionnaire. Unit of Measure: Total and individual mean scores on 5-point Likert scale (1 = completely disagree, 5 = completely agree) Scoring: Each subscale consists of 4 items; subscale scores range from 4 to 20 Interpretation: Higher scores indicate greater perceived acceptability, feasibility, or appropriateness of the intervention |
At 2 months and 6 months of treatment
|
|
Perceived acceptability, feasibility, and fit of the intervention (Qualitative measure)
기간: After 6 months of implementation phase
|
Semi-structured qualitative interviews and focus group discussions will explore participants' perceptions of the intervention's acceptability, feasibility, and fit. Unit of Measure: Thematic findings from qualitative analysis Interpretation: Interview data will be thematically coded and analyzed to identify key barriers, facilitators, and contextual factors. |
After 6 months of implementation phase
|
|
Adoption rate
기간: Through study completion, an average of 1 year
|
Rate of uptake (number of participants who agree to use the CARE TB strategy divided by total number offered) |
Through study completion, an average of 1 year
|
|
Patient fidelity to intervention
기간: 8 weeks following enrolment
|
Rate of drop-out (count of individuals who fulfill any of the following: withdraw from the study, switch arms, appointment no-show) |
8 weeks following enrolment
|
|
Healthcare providers (HCP) fidelity to intervention
기간: 8 weeks following enrolment
|
Rate of reengagement attempt (count of reminders sent to reestablish VOT over total number of missed VOT appointments) |
8 weeks following enrolment
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Reena Rajasuriar, University of Malaya
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- NMRR ID 23-03504-DLE (IIR)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
Individual participant data that underlie the results reported following deidentification.
IPD 공유 기간
Beginning 3 months following publication and no end date.
IPD 공유 액세스 기준
Investigators whose proposed used of data has been approved by independent review. Proposals should be submitted to kohhuimoon@moh.gov.my. To gain access, a data sharing agreement must be signed.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
- ANALYTIC_CODE
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .